Business
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disease which was co-developed by Eisai and BioArctic, has received the 9th Bioindustry Award from the Japan Bioindustry Association (JBA).
About this update from Biogen Inc.
[{"type":"text","content":"STOCKHOLM, July 16, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disease which was co-developed by Eisai and BioArctic, has received the 9th Bioindustry Award from the Japan Bioindustry Association (JBA).","length":388,"tagName":"p"},{"type":"text","content":"Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear amyloid-beta from the brain, thereby altering the course of the disease.","length":537,"tagName":"p"},{"type":"text","content":"Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.","length":381,"tagName":"p"},{"type":"text","content":"The information was released for public disclosure, through the agency of the contact person below, on July 16, 2025, at 9:30 a.m. CET. ","length":135,"tagName":"p"},{"type":"text","content":"For further information, please contact: Oskar Bosson, VP Communications and IRE-mail: [email protected]: +46 70 410 71 80","length":143,"tagName":"p"},{"type":"text","content":"About BioArctic AB","length":18,"tagName":"p"},{"type":"text","content":"BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad ...